Synlogic, Inc. (SYBX) Balance Sheet

The consistent decline in total assets suggests that the company is effectively consuming its remaining value to cover final operational costs. Investors should monitor whether the current asset trajectory will leave any residual value for shareholders after all wind-down liabilities are settled.

While the high current ratio appears superficially healthy, it is a byproduct of the company's transition to a non-operating state rather than operational efficiency. The lack of incoming revenue means this liquidity is strictly finite and subject to rapid depletion by administrative and legal wind-down expenses.

The persistent negative retained earnings highlight the failure of the company's synthetic biology platform to achieve commercial viability. This structural deficit suggests that any future equity value is entirely dependent on the successful monetization of intellectual property rather than the underlying business operations.